Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 17 for:    Recruiting, Enrolling by invitation Studies | Interventional Studies | glioma | United States | First posted from 04/01/2019 to 07/31/2019

Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03935685
Recruitment Status : Recruiting
First Posted : May 2, 2019
Last Update Posted : May 2, 2019
Sponsor:
Information provided by (Responsible Party):
Daniela A. Bota, University of California, Irvine

Brief Summary:
The purpose of the study is to estimate the ability of mirtazapine to reduce depression, nausea, and vomiting, and maintain weight in depressed glioma patients undergoing Temozolomide (TMZ) therapy. Of equal importance, the investigators will monitor the tolerability of Mirtazapine in these patients over the course of the study.

Condition or disease Intervention/treatment Phase
Glioma of Brain Drug: Mirtazapine (Remeron) Early Phase 1

Detailed Description:

Research Hypothesis: For glioma patients undergoing TMZ chemotherapy, Mirtazapine will address TMZ-associated nausea and vomiting (CINV) and weight loss in addition to depression. Mirtazapine acts as an antagonist at the 5-HT3 receptor, which may explain its anti-emetic properties. Mirtazapine is also an appetite stimulant, which may help curb the weight loss associated with TMZ chemotherapy.

Specific aim 1: To administer the Beck Depression Inventory to approximately 100 patients meeting the inclusion/exclusion criteria in order to identify at least 36 with clinical depression (defined as total score >= 21).

Specific aim 2: To put at least 36 clinically depressed patients identified in aim one on mirtazapine for eight weeks.

Specific aim 3: To administer the Beck Depression Inventory to patients from aim two at four weeks and at eight weeks of treatment with mirtazapine.

Specific aim 4: To document weight and frequencies of nausea, vomiting, and insomnia among participants over the course of the study.

Specific aim 5: To document adverse events experienced by participants over the course of the study and determine, to the extent possible, if mirtazapine is the cause.

The investigators will:

  1. Assess changes in the distribution of depression scores as measured by the Beck Depression Inventory (a self-administered instrument extensively used and validated in glioma studies) from baseline to after eight weeks of treatment with mirtazapine.
  2. Assess changes in nausea, vomiting, Sleeping and body weight between baseline and the eight-week follow-up visit,
  3. Document the trajectory of changes in depression, nausea, vomiting, and weight over the three study time points (baseline, four-week, and eight-week visit).
  4. Lastly, collect information on the tolerability of mirtazapine in our patient population.

Main Research Hypothesis: The investigators hypothesize that the mirtazapine regimen will improve depression scores at eight-weeks, compared to baseline scores. Further, the investigators hypothesize that the mirtazapine regimen will limit the reduction of weight and the incidence of nausea/vomiting and insomnia at eight weeks compared to baseline.


Layout table for study information
Study Type : Interventional
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study of Mirtazapine for the Dual Treatment of Depression and Temozolomide-Induced Nausea and Vomiting (CINV) in Newly-Diagnosed High-Grade Glioma Patients on Temozolomide Therapy
Actual Study Start Date : February 26, 2019
Estimated Primary Completion Date : August 9, 2020
Estimated Study Completion Date : August 9, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: mirtazapine in glioma patients treated with Temozolomide
Using the well-known Beck Depression Inventory, we will assess the changes in depression scores from baseline to after four and eight weeks of treatment with mirtazapine. We will also assess the change in nausea, vomiting, and weight at the same time points, and collect information on tolerability of mirtazapine throughout the course of the study.
Drug: Mirtazapine (Remeron)
Eligible patients should start Mirtazapine 15mg and stay there unless not tolerated, If there is no improvement in nausea dose can be increased to 30 mg and respectively 45 mg, 4 days apart. If excessive sleep, dose can be doubled. Patients should not take tryptophan while they are part of the study.




Primary Outcome Measures :
  1. Depression level in glioma patients on temozolomide therapy treated with Mirtazapine [ Time Frame: 8 weeks ]
    The assessment is conducted using the Beck Depression Inventory. The scoring scale ranges from 1 to 63. Participants with a baseline depression score of 21 or more will be classified as depressed and will be issued a prescription for mirtazapine. Total depression score between baseline and eight weeks will be compared for each patient. Distributional properties of the data will be assessed using appropriate statistical method to examine whether there is statistically significant improvement or not.

  2. Patient Weight Change [ Time Frame: 8 weeks ]
    To estimate the ability of mirtazapine to maintain weight in depressed glioma patients undergoing Temozolomide (TMZ) therapy. Weight change for each patient between baseline and 8 week will be calculated and analyzed using applicable statistical method.

  3. Frequency and grade of nausea and vomiting in depressed glioma patients on temozolomide therapy treated with Mirtazapine [ Time Frame: 8 weeks ]
    To assess the patient's level of nausea and vomiting on a nausea/vomiting scale of 1 to 7. Lower value indicates less nausea and vomiting; while higher value indicates more nausea and vomiting. Data will be assessed using appropriate statistical method to examine whether there is statistically significant improvement or not.

  4. Incidence of Treatment-Emergent Adverse Events [ Time Frame: 8 weeks ]
    To monitor the adverse event of Mirtazapine over the course of the study. AEs will be graded according to CTCAE V5.


Secondary Outcome Measures :
  1. Percentage of adherence to mirtazapine regimen [ Time Frame: 8 weeks ]
    The percentage will be calculated based on patient's pill diary entries. Higher percentage indicates patient is more compliant.

  2. Frequency of dose modifications of mirtazapine [ Time Frame: 8 weeks ]
    The dose of mirtazapine can be adjusted based on patients' conditions and adverse event reports per protocol. This is defined as the number of times that the mirtazapine dose has to be modified for each patient.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Understand and voluntarily sign and date an informed consent document prior to any study related assessments/procedures are conducted.
  • Histologically confirmed diagnosis of glioma
  • No prior treatment with temozolomide TMZ
  • Patient will receive temozolomide TMZ therapy as part of their standard treatment.
  • Males and Females ≥18 years of age at the time of signing the informed consent document. Able to understand consent forms and study materials in English
  • Willing to use approved methods of contraception for duration of study
  • Karnofsy Performance Score (KPS) of at least 60
  • Patients should have stopped any anti-depressant medications by standard of care at least a month before enrolling in the trial
  • Willing and able to adhere to the study visit schedule and other protocol requirements.
  • Adequate hematological, renal, and hepatic function (assessment performed within 14 days prior to starting treatment):

    • Absolute neutrophil count ≥ 1.5 X 109 /L
    • Platelets ≥ 100 X 109 /L
    • Serum creatinine, Total serum bilirubin ≤ 1.5 times upper limit of laboratory normal
    • AST, ALT, Alk Phos ≤ 2.5 times upper limit of laboratory normal

Exclusion Criteria:

  • Prior treatment with other chemotherapy drugs for glioma
  • Known hypersensitivity to Mirtazapine and 5-HT3 receptor antagonists
  • Life expectancy of less than three months
  • Pregnancy or breastfeeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03935685


Contacts
Layout table for location contacts
Contact: UC Irvine Health Chao Family Comprehensive Cancer Center 1-877-UC-STUDY UCstudy@uci.edu

Locations
Layout table for location information
United States, California
UC Irvine Health/Chao Family Comprehensive Cancer Center Recruiting
Orange, California, United States, 92868
Contact: Chao Family Comprehensive Cancer Center University of California, Irvine Medical Center    877-827-8839    UCstudy@uci.edu   
Sponsors and Collaborators
University of California, Irvine
Investigators
Layout table for investigator information
Principal Investigator: Daniela Bota, MD PHD University of California, Irvine

Layout table for additonal information
Responsible Party: Daniela A. Bota, Associate Dean, Clinical Research, University of California, Irvine
ClinicalTrials.gov Identifier: NCT03935685     History of Changes
Other Study ID Numbers: UCI 18-83
First Posted: May 2, 2019    Key Record Dates
Last Update Posted: May 2, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioma
Depression
Behavioral Symptoms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Temozolomide
Mirtazapine
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antidepressive Agents
Psychotropic Drugs
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Adrenergic alpha-2 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents